Kornimate/medical-research-clean huggingface dataset:
pre-prostatectomy celecoxib or placebo

Conditions: Adenocarcinoma of the Prostate; Prostate Cancer

Summary: this study will seek to determine if the downstream effects of cyclooxygenase-2 (cox-2) inhibition suggested by preclinical systems occur in human prostate cancer. to answer this question, men who have chosen prostatectomy will be randomly assigned to preoperative treatment with celecoxib or placebo for four weeks. carefully collected tumor, premalignant, and benign prostate tissue will then be examined for apoptosis, androgen receptor and prostaglandin e2 levels. tumor cox-2 expression will be correlated with observed treatment effects. the data generated by this study will serve as a foundation for the development of cox-2 targeted therapies for prostate cancer, will provide preliminary evidence for larger scale clinical trials aimed at treatment and prevention of prostate cancer, and will validate current preclinical models used to study cox-2 in prostate cancer.

primary objective i. to determine if cox-2 inhibition with celecoxib significantly increases apoptosis in human adenocarcinoma of the prostate. secondary objectives i. to determine if cox-2 inhibition with celecoxib reduces levels of prostaglandin e2 and androgen receptor in fresh tumor tissue collected at prostatectomy ii. to collect pre- and postoperative serum prostate specific antigen (psa) for exploratory analyses iii. to determine the effect of celecoxib on adverse effects, perioperative surgical complications and post surgery analgesic use

Eligibility criteria:
inclusion criteria: * histopathologically or cytologically proven adenocarcinoma of the prostate and planned prostatectomy * age \>= 18 * performance status (ecog \<= 2) * hemoglobin \> 10 g/dl (within 4 weeks) * creatinine \<= 1.5 mg/dl * signed informed patient consent exclusion criteria: * other preoperative or prior treatment directed at prostate cancer * significant active medical illness which in the opinion of the investigator would preclude protocol treatment * use of non-steroidal anti-inflammatory agents within seven days of celecoxib treatment * hypersensitivity to celecoxib * a history of asthma, urticaria, or anaphylaxis precipitated by an nsaid * history of significant upper gastrointestinal bleeding or active peptic ulcer disease * current treatment with anticoagulants * allergy to sulfonamide

Keywords: prostate cancer nsaids chemoprevention celecoxib cox-2 inhibitors
intermittent preventive treatment in infant in mali

Conditions: Malaria

Summary: studies have shown that intermittent preventive treatment in infants (ipti) with sulfadoxine-pyrimethamine (sp)reduced the incidence of clinical malaria and anemia without modifying infants' serological response to epi vaccines. thus ipti was seen as a potential public health tool of great benefit to the children of africa and a logical addition to the immunization plus package. the objectives of this operational researcher were * to develop an implementation model for ipti in the health care system in mali * to assess its impact on the epi vaccines and other health interventions coverage * and on molecular makers of resistance to sp

the study was implemented in districts of the region of koulikoro; the district of koulikoro and the district of kolokani. the whole district of koulikoro was covered by the intervention while in kolokani, the 22 health areas (sub districts) were randomized in 1:1 ratio with the intervention in 11 health areas and the other 11 serving as control for the assessment of the impact of ipti implementation on epi vaccines and other health interventions coverage as well as its impact on the resistance to sp. the implementation consisted of administration of ½ tablet of sulfadoxine -pyrimethamine with epi vaccines (dtp2, dtp3 and measles vaccine) from december 2006 to december 2007.

Eligibility criteria:
inclusion criteria: * resident of kolokani, mali * age less than 24 months exclusion criteria: * not resident of kolokani * age of 24 months or above

Keywords: malaria intermittent preventive treatment epi vaccine coverage resistance of p. falciparum to sulfadoxine- pyrimethamine
management in intensive care unit of life-threatening keto-acidosis

Conditions: Ketoacidosis

Summary: patients hospitalized in intensive care between january 2014 and december 2023 for ketoacidosis complicated by organ failure in participating departments.

analysis of patients with international statistical classification of diseases and related health problems coding compatible with inclusion * selection of patients eligible for inclusion based on review of medical records (verification of inclusion and non-inclusion criteria) * telephone contact and sending of the information letter on participation in the study and research of the patient's non-opposition to his participation and the processing of his data. * collection of retrospective data * phone call to collect prospective data

Eligibility criteria:
inclusion criteria: * major (age ≥ 18 years old) * hospitalized in intensive care between january 2014 and december 2023 for ketoacidosis complicated by organ failure in the participating departments. * diagnosis of ketoacidosis judged to be the main cause of the severity of the clinical condition. * blood potential hydrogen \< 7.15 and bicarbonates \< 10mmol/l in the first 12 hours of treatment. * presenting at least one of the 3 organ failures during hospitalization among: * use of extra-renal purification for acute renal failure * administration of pressor amines * use of mechanical ventilation exclusion criteria: * metabolic acidosis primarily of an origin other than ketonic * refusal to participate or opposition to the processing of their data * patient under guardianship or curators
a randomized sham-controlled study of pulmonary vein isolation in symptomatic atrial fibrillation

Conditions: Atrial Fibrillation

Summary: this is a double blinded randomised placebo-controlled trial comparing the effects of catheter ablation (cryoablation) versus a placebo procedure on atrial fibrillation burden, symptoms and quality of life


Eligibility criteria:
inclusion criteria: * age greater than or equal to 18 years * symptomatic paroxysmal or persistent atrial fibrillation despite at least one antiarrhythmic drug (aad type i or iii, β-blocker or aad intolerance). * referred for catheter ablation exclusion criteria: * long term persistent af (continuous episode lasting more than 1) * prior left atrium catheter or surgical atrial fibrillation ablation * patients with other arrhythmias requiring ablative therapy * left atrium (la) ≥5.5 cm * any cardiac surgery or percutaneous coronary intervention (pci) within three months prior to enrolment. * awaiting cardiac surgery or pci * myocardial infarction within three months prior to enrolment. * stroke or transient ischemic attack (tia) within three months prior to enrolment * unstable angina * any significant congenital heart defect corrected or not (including atrial septal defects or pv abnormalities) but not including patent foramen ovale. * any condition contraindicating chronic anticoagulation * any untreated or uncontrolled hyperthyroidism or hypothyroidism * severe chronic kidney disease (stage v, requiring or almost requiring dialysis, glomerular filtration rate (gfr) \< 15 ml / min) * patients with metallic prosthetic valves * pregnant or breastfeeding women * medical conditions limiting expected survival to \<1 year * history of claustrophobia or panic attacks * left ventricular ejection fraction (lvef) less than 35%

Keywords: atrial fibrillation ablation cryoablation
to observe the clinical effect of femoral nerve block with low concentration of ropivacaine based on dpn grading

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study was to quantitatively standardize the performance of patients with dpn with different course of disease using high-frequency ultrasound, and to design experiments to verify the conclusion that dpn patients with peripheral nerve damage increased nerve sensitivity to local anesthetic drugs and increased block time, and to achieve the same blocking effect by using low-concentration local anesthetic drugs, so as to reduce the probability of complications such as transient nerve injury, severe nerve injury, and local anesthetic poisoning.

clinically, through the correlation study between the serum choliphin concentration and the degree of neuropathy (cross-sectional area) of patients with dpn (scale standardization) of different course of disease and the degree of neuropathy under ultrasound, the dpn was standardized after conclusion, and then the clinical study was designed to use low concentrations of ropivacaine to perform nerve blocks at the same site in patients with dpn of different grades, and the time t of the first use of the analgesic pump after the primary outcome measures, the electrical stimulation threshold during nerve block, and the secondary outcome indicators were the threshold of electrical stimulation during nerve block, sensory and motor block time-to-occur to assess the effect of nerve block.

Eligibility criteria:
inclusion criteria:all patients met the 1999 who diagnostic criteria for diabetes. - exclusion criteria:(1) type 1 diabetes; (2) peripheral neuropathy obviously caused by other reasons; (3) patients with neuropathy caused by diabetic foot ulcers and gangrene, as well as known history of bone and joint trauma or surgery of the lower limbs; (4) contraindications to peripheral nerve block (such as local anesthetic allergy, coagulation dysfunction, peripheral infection, etc.) (5) contraindications to drug components of postoperative analgesic pumps; (6) existing opioid therapy. -
to study the effect of adjunctive oral methylprednisolone therapy in pediatric urinary tract infection

Conditions: Urinary Tract Infection

Summary: purposes of this study will be as follows: 1. to design a prospective, randomized, and open-labeled study to investigate the effect and the side effect of mpd in combination with conventional antibiotics to affect clinical course, outcome, and medical expenses. 2. to compare level of the urinary and serum cytokines before and after received mpd for the following sub-aim: i. to determine the population who is benefit from mpd to reduce the severity of clinical course and subsequent renal scarring. ii. to understand the mechanism by which the mpd could shorten the clinical course and reduce the renal scarring.

the urinary tract infection (uti) is a common etiology of the febrile children and the acute pyelonephritis (apn) happen in 70% children with the first febrile uti. after the first apn, the irreversible renal scarring takes place in about 40% patients. the sequela of the renal scarring includes chronic kidney disease, hypertension, the complication during the pregnancy, and even the end stage of renal diseases. due to the progression of the pathophysiology of the pyelonephritis and the renal scarring in the past years, we understand that the inflammation is one of the important mechanisms. therefore, there are many animal studies clarifying the role of the anti-inflammation or antioxidant to reduce the renal scarring. in our previous studies, dr. chiou y.y. and colleagues has provided the evidence that the adjunctive methylprednisolone (mpd) can decrease the risk of the renal scarring for patients with high risk apn, which was defined as inflammatory volume more than 4.6 ml on technetium-99m-labeled dimercaptosuccinic acid scan or abnormal renal ultrasonography results. our study is the first human study demonstrating the solution for the renal scarring. however, whether this result can be applied to the whole spectrum of the uti is still unknown. purposes of this study will be as follows: 1. to design a prospective, randomized, and open-labeled study to investigate the effect and the side effect of mpd in combination with conventional antibiotics to affect clinical course, outcome, and medical expenses. 2. to compare level of the urinary and serum cytokines before and after received mpd for the following sub-aim: i. to determine the population who is benefit from mpd to reduce the severity of clinical course and subsequent renal scarring. ii. to understand the mechanism by which the mpd could shorten the clinical course and reduce the renal scarring. according to these studies, we will provide a new and effective guideline to shorten disease course, save medical expenses, and decrease the risk for renal scarring sequela.

Eligibility criteria:
inclusion criteria: * 1week old \~ 16 years old children with uti exclusion criteria: * previous uti * known gu tract obstruction * severe sepsis with vital signs change * antibiotics used

Keywords: urinary tract infection methylprednisolone
evaluation of meningococcal c vaccine programmes in canadian children

Conditions: Meningococcal Sero-type C Infection

Summary: the purpose of the study is to see which of the three current provincial meningococcal c conjugate vaccine schedules in canada provide the longest lasting protection against meningococcal c disease and to see if a booster vaccination is needed.

in 2002-2005, canada introduced universal menc programmes consisting of 1,2 or 3 infant doses. most are one (12 mth) dose. high rates of serogroupc disease in 2000 and 2001 prompted some provinces to launch universal menc vaccination programmes in 2002. the goal was to provide protection in infancy and early childhood (the time of most risk) with the hope that the protection would extend throughout adolescence (the second highest risk). it is unclear if early multi-dosing or 1 dose programmes would offer better protection (lack of data). each province in canada has chosen different meningococcal c conjugate vaccine provision schedules for the primary vaccinations. this study will look at short term protection after the differing provincial series of vaccinations has been given and compare those who do not get primary vaccination under 1 year of age (ns) with two schedules of primary immunization (bc at 2 and 4 mths and alberta at 2 months). a blood sample will be collected at 12-13 mths for this comparison. a booster vaccination of the current provincial men c vaccine will be provided at 12 months. another blood sample will be collected 1 mth later to look at the difference in responses between the groups (different provincial primary vaccination schedule). 2 years and 4 years later (at age 3 and age 5), another blood sample will be collected to look at the difference in long term protection of the groups where the primary schedule was different.

Eligibility criteria:
inclusion criteria: * 12-13 mths of age * over 34 weeks gestation * healthy children * having had all vaccinations of meningococcal c vaccine per the recommended schedule for their respective province within a month of the recommended age - documented. * communication in english exclusion criteria: * no contraindication to receiving 12 mth dose of menc vaccine * no other menc vaccine or menc disease

Keywords: meningococcal c vaccine meningitis study canadian vaccine schedule prevention of meningococcal c disease
effect of inpatient diabetes management on outpatient glycemic control

Conditions: Diabetes Mellitus, Type 2

Summary: the hypothesis of this study is that using hospital admission to identify patients with poorly controlled diabetes (hemoglobin a1c levels \>8%), and intervening during the hospitalization with targeted inpatient diabetes management will improve glycemic control at 3 and 12 months, with inpatient glycemic control, quality of life, and diabetes self-efficacy serving as secondary endpoints.

the study is a randomized, controlled trial of targeted inpatient diabetes management versus usual care in 70 general medical and surgical inpatients over age 18 with type 2 diabetes and hemoglobin a1c levels greater than 8% who are followed in partners-affiliated primary care practices. in addition, we will enroll a prospective chart review cohort matched for age, sex, and hba1c level whose course we will follow for one year after discharge to determine the patter of glycemia among patients who are not enrolled in a clinical trial.

Eligibility criteria:
inclusion criteria: * age \> 18 years * known diagnosis of type 2 diabetes by history with outpatient prescription of oral hypoglycemic medication or insulin * hemoglobin a1c \> 8.0% within the prior 12 months, or if not known, fasting blood glucose greater than 200 mg/dl on sliding scale regular insulin. * partners-affiliated primary care physician exclusion criteria: * screening hba1c returns less than 8%. * diabetic ketoacidosis (dka) as a primary reason for admission (admission blood glucose \> 250 mg/dl with arterial ph \< 7.30 or serum bicarbonate level \< 15 mg/dl), or development of dka during admission. * hyperosmolar hyperglycemic syndrome as a primary reason for admission (admission blood glucose \> 400 mg/dl and plasma osmolality \> 315 mosm/kg. * pregnancy, ruled out by urine hcg test at screening after consent is obtained in all women who continue to have menstrual cycles. * anemia with hemoglobin \< 9 g/dl, recent blood transfusion, or need for blood transfusion (interferes with interpretation of hemoglobin a1c assay) * end stage liver disease with prothrombin time \> 15 seconds and albumin \<3 mg/dl * end stage renal disease: stage iv (glomerular filtration rate \<30 mg/dl) or v chronic kidney disease * treatment with corticosteroids * icu transfer * inability to self-administer insulin * hypoglycemia unawareness: patient lacks sensation of common signs of blood glucose \< 60 mg/dl (tachycardia, diaphoresis, hunger, confusion, fatigue). * projected survival \< 1 year
prediction of post-cesarean section pain

Conditions: Postoperative Pain

Summary: the purpose of this study is to determine if dynamic psychophysical testing along with genetic screening will allow to identify pre-operatively women who will suffer severe acute pain post-operatively and the subset who may experience chronic pain following cesarean section.


Eligibility criteria:
inclusion criteria: * women age 18-50 scheduled for an elective cesarean section (1st or 2nd cesarean section) exclusion criteria: women who: * have taken opioids, acetaminophen, or nsaids 48 hrs prior to psychophysical testing * have had more than two previous cesarean sections * have a vertical abdominal incision from a prior cesarean section * are non-english speaking * have mental health issues * have a failure of spinal anesthetic and require conversion to general anesthesia * have a vertical uterine incision performed during ongoing cesarean section * have a previous vertical uterine scar discovered during ongoing cesarean section
ability to cope with type 1 diabetes

Conditions: Depression

Summary: the purpose of this study is to learn about the relationship that exists between coping skills and blood glucose control. in addition to this, we will study the effect of type 1 diabetes on coping skills in different age groups, genders, ethnicities, socioeconomic groups, and the duration of diabetes.

coping with type 1 diabetes can be very difficult. type 1 diabetes is a very unique chronic disease because it requires constant attention to several responsibilities such as daily glucose monitoring, multiple daily insulin doses, and strict diet and exercise. several studies have shown that increased rates of poorer glucose control are a result of struggling to cope with type 1 diabetes. this may be due to the fact that many type 1 diabetics experience a feeling of exhaustion, or "burnout," after a certain period of time due to an overwhelming amount of responsibility. in our study we would like to determine how children's ability to cope with diabetes affects glucose control. by completing several questionnaires, we can analyze different kinds of coping skills through a complex scoring system. these scores will then be analyzed in comparison to your glucose control using hba1c.

Eligibility criteria:
inclusion criteria: * subjects must be type 1 diabetic * english/spanish speaking * the legal guardian must be present. exclusion criteria: * non-cognitive or mentally ill * under the age of 8.0 years

Keywords: depression socioeconomic status type 1 diabetes mellitus children adolescents
investigation the effect of rectus abdominis and erector spinae muscle fatigue on the viscoelastic properties of thoracolumbal fascia

Conditions: Muscle Weakness

Summary: the rectus abdominis, which enables the trunk to flex with its activation, and the erector spinae muscles, which provide trunk extension with its activation, are among the structures located in the core region and involved in the stabilization of the spine. while the muscles in the core area actively provide the stabilization of the medulla spinalis, this stabilization is also supported by passive subsystems. passive subsystem fascia etc. creates structures. thoracolumbar fascia is one of the important fascias due to its connections with the muscles in the core area. fatigue etc. of the structures in the core area. as a result of physiological processes, their functionality may decrease, which may affect the stabilization of the core area. fatigue occurs as a result of lactic acid accumulation in the structures in the body and this process is called the recovery period. the types of exercises performed also affect the recovery period. for this reason, different exercise types such as dynamic and static can be used when creating exercise programs. due to the functions of the rectus abdominis and erector spinae muscles and thoracolumbar fascia in the body, their effects on the spine and their connections with each other; it is aimed to examine the effect of muscle fatigue in these muscles on the viscoelastic properties of the thoracolumbar fascia and their recovery rates.


Eligibility criteria:
inclusion criteria: * being a healthy individual between the ages of 18-35 * not having any chronic disease * body mass index (bmi) is 24.9 kg/m2 or lower * volunteering to participate in the study exclusion criteria: * having a chronic illness (diabetes, blood pressure, etc.) * having a diagnosed spine problem * being diagnosed with scoliosis * pilates, yoga, etc. in the last 6 months. to have done sports * beighton score of 4 or above * being diagnosed with cardiopulmonary system disease

Keywords: rectus abdominis erector spinae thoracolumbar fascia
zilver® ptx® in china

Conditions: Peripheral Artery Disease

Summary: the objective of this study is to evaluate the zilver® ptx® drug-eluting peripheral stent for treatment of lesions of the above-the-knee femoropopliteal artery in a chinese patient population.


Eligibility criteria:
inclusion criteria: * symptoms of peripheral arterial disease corresponding to rutherford classification 2-4 * stenotic (\>50% diameter stenosis) or occluded lesion of the above-the knee femoropopliteal artery * reference vessel diameter of 4-9 mm * lesion length up to 140 mm exclusion criteria: * unsuccessful arterial interventional treatment of the legs within 30 days prior to the study procedure * previous stent in the study vessel * bypass graft with an anastomosis in the study vessel * significant stenosis or occlusion of inflow tract not successfully treated prior to treating the study lesion * no patent vessel of runoff

Keywords: zilver® ptx® drug-eluting peripheral stent above-the-knee femoropopliteal artery chinese patient